Literature DB >> 26020511

Anti-cancer activity of withaferin A in B-cell lymphoma.

M K McKenna1, B W Gachuki, S S Alhakeem, K N Oben, V M Rangnekar, R C Gupta, S Bondada.   

Abstract

Withaferin A (WA), a withanolide from the plant, Ashwagandha (Withania somnifera) used in Ayurvedic medicine, has been found to be valuable in the treatment of several medical ailments. WA has been found to have anticancer activity against various solid tumors, but its effects on hematological malignancies have not been studied in detail. WA strongly inhibited the survival of several human and murine B cell lymphoma cell lines. Additionally, in vivo studies with syngeneic-graft lymphoma cells suggest that WA inhibits the growth of tumor but does not affect other proliferative tissues. We demonstrate that WA inhibits the efficiency of NF-κB nuclear translocation in diffuse large B cell lymphomas and found that WA treatment resulted in a significant decrease in protein levels involved in B cell receptor signaling and cell cycle regulation. WA inhibited the activity of heat shock protein (Hsp) 90 as reflected by a sharp increase in Hsp70 expression levels. Hence, we propose that the anti-cancer effects of WA in lymphomas are likely due to its ability to inhibit Hsp90 function and subsequent reduction of critical kinases and cell cycle regulators that are clients of Hsp90.

Entities:  

Keywords:  B-cell lymphoma; B-cell receptor signaling; DLBCL, Diffuse large B cell lymphoma; WA, Withaferin A; apoptosis; withaferin A

Mesh:

Substances:

Year:  2015        PMID: 26020511      PMCID: PMC4622669          DOI: 10.1080/15384047.2015.1046651

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  52 in total

1.  LXR-α genomics programmes neuronal death observed in Alzheimer's disease.

Authors:  Ashvinder Raina; Deepak Kaul
Journal:  Apoptosis       Date:  2010-12       Impact factor: 4.677

2.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.

Authors:  Kamalika Moulick; James H Ahn; Hongliang Zong; Anna Rodina; Leandro Cerchietti; Erica M Gomes DaGama; Eloisi Caldas-Lopes; Kristin Beebe; Fabiana Perna; Katerina Hatzi; Ly P Vu; Xinyang Zhao; Danuta Zatorska; Tony Taldone; Peter Smith-Jones; Mary Alpaugh; Steven S Gross; Nagavarakishore Pillarsetty; Thomas Ku; Jason S Lewis; Steven M Larson; Ross Levine; Hediye Erdjument-Bromage; Monica L Guzman; Stephen D Nimer; Ari Melnick; Len Neckers; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2011-09-25       Impact factor: 15.040

3.  Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically.

Authors:  Antonio Franchitto; Alessia Torrice; Rossella Semeraro; Cristina Napoli; Gennaro Nuzzo; Felice Giuliante; Gianfranco Alpini; Guido Carpino; Pasquale Bartolomeo Berloco; Luciano Izzo; Antonio Bolognese; Paolo Onori; Anastasia Renzi; Alfredo Cantafora; Eugenio Gaudio; Domenico Alvaro
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

4.  Modulation of Akt kinase activity by binding to Hsp90.

Authors:  S Sato; N Fujita; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 5.  Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.

Authors:  Kian-Huat Lim; Yibin Yang; Louis M Staudt
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 6.  New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Authors:  Robert C Rickert
Journal:  Nat Rev Immunol       Date:  2013-08       Impact factor: 53.106

Review 7.  Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone.

Authors:  Avani R Vyas; Shivendra V Singh
Journal:  AAPS J       Date:  2013-09-18       Impact factor: 4.009

8.  Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.

Authors:  Matthias Edinger; Yu-An Cao; Michael R Verneris; Michael H Bachmann; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

9.  Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells.

Authors:  Silvia D Stan; Yan Zeng; Shivendra V Singh
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

10.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  20 in total

1.  Obesity: will withaferin win the war?

Authors:  Paul T Pfluger; Matthias H Tschöp
Journal:  Nat Med       Date:  2016-09-07       Impact factor: 53.440

Review 2.  Complementary and Integrative Medicine in Hematologic Malignancies: Questions and Challenges.

Authors:  Moshe Frenkel; Kenneth Sapire
Journal:  Curr Oncol Rep       Date:  2017-10-14       Impact factor: 5.075

Review 3.  Broad-spectrum antitumor properties of Withaferin A: a proteomic perspective.

Authors:  Martin Dom; Wim Vanden Berghe; Xaveer Van Ostade
Journal:  RSC Med Chem       Date:  2019-12-16

4.  Withaferin A induces cell death and differentiation in multiple myeloma cancer stem cells.

Authors:  Mark E Issa; Muriel Cuendet
Journal:  Medchemcomm       Date:  2016-11-17       Impact factor: 3.597

5.  Essential oil from Cymbopogon flexuosus as the potential inhibitor for HSP90.

Authors:  Roopa Gaonkar; Yallappa Shiralgi; Dhananjaya B Lakkappa; Gurumurthy Hegde
Journal:  Toxicol Rep       Date:  2018-04-05

6.  Withania somnifera Induces Cytotoxic and Cytostatic Effects on Human T Leukemia Cells.

Authors:  Eleonora Turrini; Cinzia Calcabrini; Piero Sestili; Elena Catanzaro; Elena de Gianni; Anna Rita Diaz; Patrizia Hrelia; Massimo Tacchini; Alessandra Guerrini; Barbara Canonico; Stefano Papa; Giovanni Valdrè; Carmela Fimognari
Journal:  Toxins (Basel)       Date:  2016-05-12       Impact factor: 4.546

Review 7.  Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia.

Authors:  Kalubai Vari Khajapeer; Rajasekaran Baskaran
Journal:  Leuk Res Treatment       Date:  2015-12-03

Review 8.  Withaferin-A--A Natural Anticancer Agent with Pleitropic Mechanisms of Action.

Authors:  In-Chul Lee; Bu Young Choi
Journal:  Int J Mol Sci       Date:  2016-03-04       Impact factor: 5.923

9.  Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression.

Authors:  Shuichiro Okamoto; Takayuki Tsujioka; Shin-Ichiro Suemori; Jun-Ichiro Kida; Toshinori Kondo; Yumi Tohyama; Kaoru Tohyama
Journal:  Cancer Sci       Date:  2016-07-28       Impact factor: 6.716

10.  Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A.

Authors:  Karine Z Oben; Sara S Alhakeem; Mary K McKenna; Jason A Brandon; Rajeswaran Mani; Sunil K Noothi; Liu Jinpeng; Shailaja Akunuru; Sanjit K Dhar; Inder P Singh; Ying Liang; Chi Wang; Ahmed Abdel-Latif; Harold F Stills; Daret K St Clair; Hartmut Geiger; Natarajan Muthusamy; Kaoru Tohyama; Ramesh C Gupta; Subbarao Bondada
Journal:  Oncotarget       Date:  2017-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.